Search results: Found 5

Listing 1 - 5 of 5
Sort by
Microenvironment-Derived Stem Cell Plasticity

Authors: --- --- ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889453443 Year: Pages: 114 DOI: 10.3389/978-2-88945-344-3 Language: English
Publisher: Frontiers Media SA
Subject: Science (General) --- Biology --- Medicine (General) --- Allergy and Immunology
Added to DOAB on : 2018-02-27 16:16:45
License:

Loading...
Export citation

Choose an application

Abstract

Plasticity is the hallmark of stem cells. At the same time, stem cells, like any other cell type, are influenced by their microenvironment and respond to it accordingly. A specific microenvironment is defined by a variety of factors, including biological and chemical factors, cell-cell interactions, but also metabolic and mechanical cues. Such dynamic and specialized microenvironment where the stem cells reside is considered a stem cell niche. Tissue injury as well as malignant tissue alterations lead to changes in the niche influencing the plasticity and biology of residing stem cells. Similarly, the niche changes upon tissue damage, which eventually induces differentiation of stem cells and ultimately regeneration of the tissue.

Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine

Authors: --- --- --- --- et al.
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889453870 Year: Pages: 177 DOI: 10.3389/978-2-88945-387-0 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General) --- Allergy and Immunology
Added to DOAB on : 2018-11-16 17:17:57
License:

Loading...
Export citation

Choose an application

Abstract

The immune system has the double role of maintaining tissue integrity and homeostasis and of protecting the organism from possible dangers, from invading pathogens to environmentally-borne dangerous chemicals. New chemicals recognisable by the immune system are engineered nanomaterials/ nanoparticles, new agents in our environment that are becoming common due to their presence in many products, from constructions and building material (e.g., solar cells, pigments and paints, tiles and masonry materials) to daily products (e.g., food packaging, cosmetics, and cigarettes). Human beings can be accidentally exposed to engineered nanomaterials when these are released from products containing them or during production in workplaces. Furthermore, intentional exposure occurs in medicine, as engineered nanoparticles are used as tools for improving delivery of drugs and vaccines, vaccine adjuvants and contrast agents in therapeutic, preventive and diagnostic strategies. Nanoparticles that come in contact with the immune system after unintentional exposure need to be eliminated from the organism as they represent a potential threat. In this case, however, due to their peculiar characteristics of size, shape, surface charge and persistence, nanoparticles may elicit undesirable reactions and have detrimental effects on the immune system, such as cytotoxicity, inflammation, anaphylaxis, immunosuppression. Conversely, nanomedicines need to escape immune recognition/elimination and must persist in the organism long enough for reaching their target and exerting their beneficial effects. Immune cells and molecules at the body surface (airway and digestive mucosae, skin) are the first that come in contact with nanomaterials upon accidental exposure, while immune effectors in blood are those that more easily come in contact with nanomedical products. Thus, evaluating the interaction of the immune system with nanoparticles/nanomaterials is a topic of key importance both in nanotoxicology and in nanomedicine. Immuno-nanosafety studies consider both accidental exposure to nanoparticles, which may occur by skin contact, ingestion or inhalation (at doses and with a frequency that are not known), and medical exposure, which takes place with a defined administration schedule (route, dose, frequency). Many studies focus on the interaction between the immune system and nanoparticles that, for medical purposes, have been specifically modified to stimulate immunity or to avoid immune recognition, as in the case of vaccine carriers/adjuvants or drug delivery systems, respectively. The aims of this Research Topic is to provide an overview of recent strategies: 1.for assessing the immunosafety of engineered nanomaterials/nanoparticles, in particular in terms of activation of inflammatory responses, such as complement activation and allergic reactions, based on the nanomaterial intrinsic characteristics and on the possible carry-over of bioactive contaminants such as LPS. Production of new nanoparticles taking into account their effects on immune responses, in order to avoid undesirable effects on one hand, and to design particles with desirable effects for medical applications on the other hand; 2.for designing more effective nanomedicines by either avoiding or exploiting their interaction with the immune systems, with particular focus on cancer diagnosis and therapy, and vaccination. This collection of articles gives a comprehensive view of the state-of-the-art of the interaction of nanoparticles with the immune system from the two perspectives of safety and medical use, and aims at providing immunologists with the relevant knowledge for designing improved strategies for immunologically safe nanomaterial applications.

Immune responses to AAV vectors, from bench to bedside

Authors: --- --- ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889195008 Year: Pages: 95 DOI: 10.3389/978-2-88919-500-8 Language: English
Publisher: Frontiers Media SA
Subject: Allergy and Immunology --- Medicine (General)
Added to DOAB on : 2015-12-03 13:02:24
License:

Loading...
Export citation

Choose an application

Abstract

The recent wave of clinical studies demonstrating long-term therapeutic efficacy highlights the enormous potential of gene therapy as an approach to the treatment of inherited disorders and cancer. While in recent years lentiviral vectors have dominated the field of ex vivo gene therapy in man, adeno-associated virus (AAV) vectors have become the platform of choice for the in vivo gene delivery, both local and systemic.Despite the achievements in the clinic however, a number of hurdles remain to be overcome in gene therapy, these include availability of scalable vector production systems, potential issues associated with insertional mutagenesis, and concerns related to immunogenicity of gene therapeutics. For AAV vectors, clinical trials showed that immunity directed against the vector could either prevent transduction of a target tissue or limit the duration of therapeutic efficacy. Initial observations in the context of a gene therapy trial for hemophilia spurred over a decade efforts by gene therapists and immunologists to understand the mechanism and identify factors that contribute to AAV’s immunogenicity, including the prevalence of B cell and T cell immunity to wild type AAV in humans and the interaction of AAV vectors with the innate and adaptive immune system. Despite a number of important contributions in particular in the more recent past, our knowledge on the immunology of gene transfer is still rudimental; this is partly due to the fact that the basic understanding of the complex balance between tolerance and immunity to an antigen, key aspect of gene transfer with AAV, keeps evolving rapidly. However, continuing work towards a better definition of the interaction of viral vectors with the immune system has led to significant advances in the knowledge of the factors influencing the outcome of gene transfer, such as the vector dose, the immune privilege of certain tissues, and the induction of tolerance to an antigen. A better understanding of the structure-function relationship of the viral capsid has boosted the development of novel immune-escape vector variants. In addition, novel immunomodulatory strategies were established to prevent or reduce anti-capsid immunity have been developed and are being tested in preclinical models and in clinical trials. Together, these advances are bringing us closer to the goal of achieving safe and sustained therapeutic gene transfer in humans. In this research topic, a collection of Original Research and Review Articles highlights critical aspects of the interaction between gene AAV vectors and the immune system, discussing how these interactions can be either detrimental or constitute an advantage, depending on the context of gene transfer, and providing tools and resources to better understand the issue of immunogenicity of AAV vectors in gene transfer.

Molecular Research of Endometrial Pathophysiology

Authors: ---
ISBN: 9783039214952 / 9783039214969 Year: Pages: 378 DOI: 10.3390/books978-3-03921-496-9 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Social Sciences --- Sociology
Added to DOAB on : 2019-12-09 16:10:12
License:

Loading...
Export citation

Choose an application

Abstract

The endometrium has been the subject of intense research in a variety of clinical settings, because of its importance in the reproductive process and its role in women’s health. In the past 15 years, significant efforts have been invested in defining the molecular phenotype of the receptive phase endometrium as well as of various endometrial pathologies. Although this has generated a wealth of information on the molecular landscape of human endometrium, there is a need to complement this information in light of the novel methodologies and innovative technical approaches. The focus of this International Journal of Molecular Sciences Special Issue is on molecular and cellular mechanisms of endometrium and endometrium-related disorders. The progress made in the molecular actions of steroids, in the metabolism of steroids and intracrinology, in endometrial intracellular pathways, in stem cells biology, as well as in the molecular alterations underlying endometrium-related pathologies has been the focus of the reviews and papers included.

Keywords

RANK --- endometrium --- endometrial cancer --- prognosis --- immunohistochemistry --- gene expression --- endometriosis --- developmental pathway --- pathogenomics --- mesenchymal stem cells --- endometrial cancer --- mtDNA mutations --- deficit of complex I --- antioxidant response --- mitochondrial biogenesis --- mitochondrial dynamics --- mitophagy --- miRNA --- lncRNAs --- endometrial cancer --- endometriosis --- chronic endometritis --- cell contacts --- tight junction --- adherens junction --- gap junction --- endometrium --- implantation --- decidualization --- endometriosis --- endometrial cancer --- liquid biopsy --- uterine aspirate --- circulating tumour cells (CTCs) --- circulating tumour DNA (ctDNA) --- exosomes --- Vitamin D --- endometrium --- endometrial cancer --- endometrial cancer --- preclinical models --- translational research --- endometrial cancer --- type II endometrial carcinoma --- targeted therapy --- kinase inhibitor --- molecular marker --- protein kinase --- protein phosphatase --- PP2A --- PPP2R1A --- SMAP --- endometriosis --- infertility --- niche --- inflammation --- immunomodulation --- mesenchymal stem cell --- orthoxenograft --- uterine cancer --- avatar --- murine models --- personalized medicine --- targeted therapy --- preclinical studies --- translational research --- endometriosis --- TRP channels --- endometrial stromal cells --- eutopic and ectopic endometrium --- endometrial cell --- pathway --- proliferation --- decidualization --- migration --- angiogenesis --- regeneration --- breakdown --- implantation --- endometrial cancer --- orthotopic xenograft model --- estrogen dependent --- bioluminescence imaging --- contrast-enhanced CT scan --- endometrium --- adult stem cells --- endometrial regeneration --- stem cell markers --- endometriosis --- endometrial cancer --- decidualisation --- oestradiol --- aromatase --- testosterone --- dehydroepiandrosterone (DHEA) --- endometriosis --- endometrial cancer --- sulfatase --- endometriosis --- ectopic stroma --- microRNA --- small RNA sequencing --- EDN1 --- HOXA10 --- miR-139-5p --- miR-375 --- CTCF --- tumour suppressor gene --- haploinsufficiency --- zinc finger --- CRISPR/Cas9 --- cancer --- endometrial cancer --- gene editing --- phosphoinositide 3-kinase --- PIK3CA --- PIK3CB --- p110? --- p110? --- endometrial cancer --- LGR5 --- endometrium --- endometriosis --- menstrual cycle --- macrophages

Hurdles for Phage Therapy (PT) to Become a Reality

Author:
ISBN: 9783039213917 / 9783039213924 Year: Pages: 484 DOI: 10.3390/books978-3-03921-392-4 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology --- Microbiology
Added to DOAB on : 2019-12-09 11:49:15
License:

Loading...
Export citation

Choose an application

Abstract

Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.

Keywords

Staphylococcus aureus --- bacteriophage --- phage therapy --- vB_SauM-fRuSau02 --- Twortlikevirus --- antibiotic --- antimicrobial resistance --- magistral preparation --- compounding pharmacy --- phage therapy --- regulatory framework --- personalized medicine --- bacteriophage --- phage --- horizontal gene transfer --- co-evolution --- phage therapy --- industrial phage application --- antimicrobial resistance (AMR) --- Germany --- pH stability --- phage-host interactions --- genomics --- antibiotic-resistance --- phage preparation --- lysins --- biofilms --- typhoid fever --- Salmonella Typhi --- extended-spectrum beta lactamases (ESBL) --- Democratic Republic of the Congo --- bacteriophages --- MALDI-MS --- Staphylococcus --- bacteriophages --- phage therapy --- Kayvirus --- Viral proteins --- bacteriophage --- therapy --- phage therapy --- bacterial disease --- infection --- target selection --- Bacteriophage --- phage therapy --- resistance --- adaptation --- prophage --- production --- regulation --- phage therapy --- viral genomes --- best practices --- IND --- high-throughput sequencing --- bacteriophages --- phages --- food safety --- foodborne illness --- phage therapy --- history of science --- science communication --- bacteriophage --- phage therapy --- sustainable agriculture --- zoonosis --- antibiotic resistance --- phage therapy --- experimental therapy --- phage cocktails --- anti-phage antibodies --- prophage --- immunomodulation --- phage therapy --- evolution --- bacterial resistance --- virulence --- Listeria ivanovii --- bacteriophages --- alginate --- production --- disinfection --- phagodisinfection --- virus–host interactions --- bacteriophage efficacy --- gastrointestinal tract --- phage therapy --- bacteriophage --- phage therapy --- antimicrobial resistance --- antibiotic --- global health --- developing countries --- infectious disease --- bacteriophage --- phage --- phage therapy --- phage-resistance --- phage therapy --- bacterial infection --- capsule depolymerase --- antibiotic --- animal model --- bacterial resistance --- bacteriophage --- immunology --- innate immunity --- adaptive immunity --- human host --- phage-human host interaction --- bacterial infection --- antibiotic resistance --- bacteriophage --- antibiotic therapy --- phage therapy --- cases report --- abortive infection --- prophage --- adsorption --- Enterococcus --- rhamnopolysaccharide --- bacteriophage --- phage therapy --- Staphylococcus aureus --- biofilm --- antimicrobial --- frequency of resistance --- phage sensitivity --- resistance management --- nontraditional antibacterial --- bacteriophages --- phage therapy --- antibiotic resistance --- Pseudomonas aeruginosa --- Escherichia coli --- Staphylococcus aureus --- Brussels --- Belgium --- phage biocontrol --- patent landscape --- crop production --- bacteriophage --- phage therapy --- multidrug-resistant bacteria --- antimicrobial resistance --- bacteriophage therapy --- compassionate use --- antibiotic resistance --- phage therapy --- PTMP --- ATMP --- regulatory framework --- pharmaceutical paradigm shift --- clinical trial --- magistral formula --- personalized medicine --- phage therapy --- E. faecalis --- OrthoMCL --- antimicrobial resistance --- capsule --- Galleria mellonella --- Klebsiella pneumoniae --- phage therapy --- n/a --- antimicrobial resistance --- bacteriophage --- personalised medicines --- phage therapy --- pharmaceutical legislation --- regulatory framework

Listing 1 - 5 of 5
Sort by
Narrow your search